Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance

International Journal of Pharmaceutics

Volumn 422, Issue 1-2, 2012, Pages 390-397

  Ji, Xiufeng ^a,b   Gao, Yu ^a   Chen, Lingli ^a   Zhang, Zhiwen ^a   Deng, Yihui ^b   Li, Yaping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Liposome; Multi drug resistance; Nanohybrid systems; Non ionic surfactant; Paclitaxel

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREMOPHOR; GLYCOPROTEIN P; LIPOSOME; NONIONIC SURFACTANT; PACLITAXEL; POLOXAMER; RHODAMINE 123; SOLUTOL HS 15;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL CYCLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RELEASE; DRUG TRANSPORT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYDRATION; LUNG CANCER; MULTIDRUG RESISTANCE; NANOTECHNOLOGY; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLYCEROL; HUMANS; LIPIDS; LIPOSOMES; LUNG NEOPLASMS; NANOTECHNOLOGY; P-GLYCOPROTEIN; PACLITAXEL; PARTICLE SIZE; POLOXAMER; POLYETHYLENE GLYCOLS; RHODAMINE 123; SOLUBILITY; STEARIC ACIDS; SURFACE-ACTIVE AGENTS; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS;

EID: 84655174852     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.10.003     Document Type: Article

References (36)

1. Y. Akazawa, H. Kawaguchi, M. Funahashi, Y. Watanabe, K. Yamaoka, M. Hashida, and Y. Takakura Effect of interferons on P-glycoprotein-mediated rhodamine-123 efflux in cultured rat hepatocytes J. Pharm. Sci. 91 2002 2110 2115
2. E.V. Batrakova, and A.V. Kabanov Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers J. Control. Release 130 2008 98 106
3. E.V. Batrakova, S. Li, A.M. Brynskikh, A.K. Sharma, Y. Li, M. Boska, N. Gong, R.L. Mosley, V.Y. Alakhov, H.E. Gendelman, and A.V. Kabanov Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers J. Control. Release 143 2010 290 301
4. E. Borowski, M.M. Bontemps-Gracz, and A. Piwkowska Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells Acta Biochim. Pol. 52 2005 609 627 (Pubitemid 41571706)
5. Z. Cao, Y. Ma, X. Yue, S. Li, Z. Dai, and J. Kikuchi Stabilized liposomal nanohybrid cerasomes for drug delivery applications Chem. Commun. (Camb.) 46 2010 5265 5267
6. M.D. Chavanpatil, Y. Patil, and J. Panyam Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux Int. J. Pharm. 320 2006 150 156 (Pubitemid 44128700)
7. J.S. Coon, W. Knudson, K. Clodfelter, B. Lu, and R.S. Weinstein Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance Cancer Res. 51 1991 897 902
8. X. Dong, C.A. Mattingly, M.T. Tseng, M.J. Cho, Y. Liu, V.R. Adams, and R.J. Mumper Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP Cancer Res. 69 2009 3918 3926
9. T. Ganesh, C. Yang, A. Norris, T. Glass, S. Bane, R. Ravindra, A. Banerjee, B. Metaferia, S.L. Thomas, P. Giannakakou, A.A. Alcaraz, A.S. Lakdawala, J.P. Snyder, and D.G. Kingston Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3′ bridged paclitaxel analogues J. Med. Chem. 50 2007 713 725 (Pubitemid 46332984)
10. A. Goncalves, D. Braguer, K. Kamath, L. Martello, C. Briand, S. Horwitz, L. Wilson, and M.A. Jordan Resistance to taxol in lung cancer cells associated with increased microtubule dynamics Proc. Natl. Acad. Sci. U.S.A. 98 2001 11737 11742
11. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 2002 48 58 (Pubitemid 37328807)
12. C. Guo, S. Liu, C. Jiang, W. Li, Z. Dai, H. Fritz, and X. Wu A promising drug controlled-release system based on diacetylene/phospholipid polymerized vesicles Langmuir 25 2009 13114 13119
13. E.D. Hugger, B.L. Novak, P.S. Burton, K.L. Audus, and R.T. Borchardt A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro J. Pharm. Sci. 91 2002 1991 2002 (Pubitemid 36254935)
14. L.S. Jabr-Milane, L.E. van Vlerken, S. Yadav, and M.M. Amiji Multi-functional nanocarriers to overcome tumor drug resistance Cancer Treat. Rev. 34 2008 592 602
15. M. Katakam, L.N. Bell, and A.K. Banga Effect of surfactants on the physical stability of recombinant human growth hormone J. Pharm. Sci. 84 1995 713 716
16. B.A. Kerwin Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways J. Pharm. Sci. 97 2008 2924 2935
17. J.M. Koziara, P.R. Lockman, D.D. Allen, and R.J. Mumper Paclitaxel nanoparticles for the potential treatment of brain tumor J. Control. Release 99 2004 259 269 (Pubitemid 39222111)
18. C.H. Lee Reversing agents for ATP-binding cassette drug transporters Methods Mol. Biol. 596 2010 325 340
19. G.D. Leonard, O. Polgar, and S.E. Bates ABC transporters and inhibitors: new targets, new agents Curr. Opin. Investig. Drugs 3 2002 1652 1659 (Pubitemid 36266743)
20. X.J. Liang, C. Chen, Y. Zhao, and P.C. Wang Circumventing tumor resistance to chemotherapy by nanotechnology Methods Mol. Biol. 596 2010 467 488
21. L.A. Martello, H.M. McDaid, D.L. Regl, C.P. Yang, D. Meng, T.R. Pettus, M.D. Kaufman, H. Arimoto, S.J. Danishefsky, A.B. Smith, and S.B. Horwitz Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines Clin. Cancer Res. 6 2000 1978 1987 (Pubitemid 30305097)
22. L.A. Martello, P. Verdier-Pinard, H.J. Shen, L. He, K. Torres, G.A. Orr, and S.B. Horwitz Elevated levels of microtubule destabilizing factors in a taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation Cancer Res. 63 2003 1207 1213 (Pubitemid 36355832)
23. T. Minko, E.V. Batrakova, S. Li, Y. Li, R.I. Pakuplu, V.Y. Alakhov, and A.V. Kabanov Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells J. Control. Release 105 2005 269 278 (Pubitemid 40941992)
24. T. Ozben Mechanisms and strategies to overcome multiple drug resistance in cancer FEBS Lett. 22 2006 2903 2909 (Pubitemid 43729172)
25. C. Saengkhae, C. Loetchutinat, and A. Garnier-Suillerot Kinetic analysis of rhodamines efflux mediated by the multidrug resistance protein (MRP1) Biophys. J. 85 2003 2006 2014 (Pubitemid 37052280)
26. Q.L. Sun, H.F. Sha, X.H. Yang, G.L. Bao, J. Lu, and Y.Y. Xie Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-taxol J. Cancer Res. Clin. Oncol. 137 2010 521 532
27. G. Szakács, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nat. Rev. Drug Discov. 5 2006 219 234 (Pubitemid 43336035)
28. B. Tan, D. Piwnica-Worms, and L. Ratner Multidrug resistance transporters and modulation Curr. Opin. Oncol. 12 2000 450 458 (Pubitemid 32268882)
29. T.L. Weigel, M.T. Lotze, P.K. Kim, A.A. Amoscato, J.D. Luketich, and C. Odoux Paclitaxel-induced apoptosis in non-small cell lung cancer cell lines is associated with increased caspase-3 activity J. Thorac. Cardiovasc. Surg. 119 2000 795 803 (Pubitemid 30395478)
30. H.L. Wong, R. Bendayan, A.M. Rauth, H.Y. Xue, K. Babakhanian, and X.Y. Wu A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer lipid hybrid nanoparticle system J. Pharmacol. Exp. Ther. 317 2006 1372 1381 (Pubitemid 43764144)
31. T. Yamagata, H. Kusuhara, M. Morishita, K. Takayama, H. Benameur, and Y. Sugiyama Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients Drug Metab. Dispos. 35 2007 1142 1148 (Pubitemid 46956435)
32. C.P. Yang, F. Galbiati, D. Volonte, S.B. Horwitz, and M.P. Lisanti Upregulation of caveolin-1 and caveolae organelles in taxol-resistant A549 cells FEBS Lett. 439 1998 368 372 (Pubitemid 28546677)
33. T. Yang, F.D. Cui, M.K. Choi, J.W. Cho, S.J. Chung, C.K. Shim, and D.D. Kim Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation Int. J. Pharm. 338 2007 317 326 (Pubitemid 46777245)
34. C. Zhang, Q. Ping, and H. Zhang Self-assembly and characterization of paclitaxel-loaded N-octyl-O-sulfate chitosan micellar system Colloids Surf. 39 2004 69 75 (Pubitemid 39473356)
35. X.G. Zhang, J. Miao, Y.Q. Dai, Y.Z. Du, H. Yuan, and F.Q. Hu Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells Int. J. Pharm. 361 2008 239 244
36. Y. Zhang, H. Li, H. Wang, F. Su, R. Qu, D. Yin, J. Dai, Y. Li, and X. Chen Syl611, a novel semisynthetic taxane derivative, reverses multidrug resistance by p-glycoprotein inhibition and facilitating inward transmembrane action Cancer Chemother. Pharmacol. 66 2010 851 859